Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.830
-0.024 (-2.84%)
Dec 20, 2024, 4:00 PM EST - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
12.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
STRATA Skin Sciences | 32.68M |
Sol-Gel Technologies | 11.71M |
Aspira Women's Health | 8.96M |
Evoke Pharma | 8.62M |
TherapeuticsMD | 1.60M |
Eterna Therapeutics | 598.00K |
AIM ImmunoTech | 190.00K |
IMNN News
- 2 days ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 11 days ago - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - GlobeNewsWire
- 26 days ago - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 6 weeks ago - IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - GlobeNewsWire
- 7 weeks ago - IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire